Dundas Partners LLP Bristol Myers Squibb CO Transaction History

Dundas Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $9.66 Million - $11.3 Million	-180,191 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$61.91 - $67.42 $600,279 - $653,704	9,696 Added 5.69%	180,191 $12 Million
Q4 2020 Feb 12, 2021	BUY	$57.74 - $65.43 $767,537 - $869,760	13,293 Added 8.46%	170,495 $12.1 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $289,953 - $421,370	6,249 Added 4.14%	157,202 $8.78 Million
Q4 2019 Feb 07, 2020	BUY	$49.21 - $64.19 $180,108 - $234,935	3,660 Added 2.48%	150,953 $9.68 Million
Q2 2019 Aug 01, 2019	BUY	$44.62 - $49.34 $127,791 - $141,309	2,864 Added 1.98%	147,293 $6.68 Million
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $2.15 Million - $2.43 Million	38,987 Added 36.97%	144,429 $11.6 Million
Q2 2018 Jul 26, 2018	SELL	$50.53 - $62.98 $1.02 Million - $1.28 Million	-20,265 Reduced 16.12%	105,442 $5.85 Million
Q1 2018 Jun 06, 2018	BUY	$59.92 - $68.98 $7.53 Million - $8.67 Million	125,707 New	125,707 $7.58 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Dundas Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Dundas Partners LLP with notifications on news.